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Gaucher disease (GD) is one of the most common lysosomal
storage disorders with prevalence of 1 in 75,000 live births
worldwide [1]. It is due to inherited (autosomal recessive)
deficiency of lysosomal enzyme ß-glucocerebrosidase (GC).
This deficiency leads to accumulation of glucocerebroside in
lysosomes of the cells of the macrophage–monocyte lineage
and subsequently leads to anemia, thrombocytopenia,
hepatomegaly, splenomegaly, bone infarcts, aseptic necrosis
of bones and osteoporosis [2].
However, some manifestations cannot be explained by glu-
cocerebroside storage alone as immunologic abnormalities,
increased prevalence of malignancy, neurologic abnormalities,
cardiac valve manifestations and hypertension [3].
GD is classified into three main types: type I (adult type)
which is the most common type. The age of onset and rate
of progression varies widely ranging from asymptomatic dis-
ease to disability in toddlers. It lacks involvement of the brain
and the so called non-neuropathic GD although some patients
and carriers are risk prone for parkinsonism in adult life [4].
Type II (infantile type or acute neuropathic) which has as
infantile onset of severe CNS involvement and death in early
childhood. Type III has mild CNS involvement in early child-
hood or adolescent and has an indolent coarse. However, in
Asian and Arab countries including Egypt, type III is the com-
monest type [3,5]. A perinatal lethal form and a cardiovascular
form have been also described. [6,7]
Diagnosis can be confirmed by high chitotriosidase level,
low GC enzyme activity and mutation analysis and more than
300 mutations have been identified in this autosomal recessive
disease [8,9].
The basic goals of treatment are elimination or improve-
ment of symptoms, prevention of irreversible complications,
and improvement in the overall health and quality of life.
An additional goal in children is optimization of growth
[10,11].
2. Aim of review
The aim of this review is to high light the current and future
treatment options for patients with Gaucher disease and to
compare their effects and side effects.
3. Therapeutic options
3.1. Enzyme replacement therapy (ERT)
Macrophage-targeted enzyme replacement therapy (ERT) has
long been the standard of care. It is not a cure for GD, i.e.: itdoes not repair the underlying genetic defect but it can reverse
and prevent numerous manifestations of GD type 1 [12–14].
The goal of ERT is to provide sufficient amount of enzyme
to allow processing of accumulated material for patients
including children with GD who manifest signs and symptoms
[10]. ERT is well established as being effective in reducing
hematologic, visceral and bone symptoms. Early treatment
may prevent development of irreversible pathology. Treatment
also improves growth and reduce the impact of disease on
physical and psychological development However, it comes
with a therapeutic burden due to the need for regular life-
long IV therapy as well as high cost [11].
In order to establish the severity of disease and to tailor the
initial and maintenance ERT dose, a classification in high- and
low-risk type 1 GD patients has been suggested by a panel of
experts [15].
Response to ERT was documented by international
collaborative Gaucher group (ICGG) registry with decreased
liver and spleen volumes and increase in hemoglobin levels
and platelet counts within 6 months of therapy [5,16]. How-
ever, GD I involvement beyond the monocyte/macrophage
system may underlie unmet treatment needs with respect to
skeletal, pulmonary, and immune manifestations [17]. Like-
wise, the CNS manifestations of type II and III GD do not
respond well to ERT due to the inability of exogenous enzyme
to cross the BBB [18].
The standard dose is 60 units/kg every two weeks and can
be individualized according to response and requirements.
Higher doses may be needed in the initial stage of GD type
III and lower doses may be given as a maintenance dose in
GD type I [19].
ERT includes imiglucerase (Cerezyme), velaglucerase alfa
(VPRIV), and taliglucerase alfa (Elelyso). Historically, most
patients received the recombinant enzyme imiglucerase [20].
All are recombinant GC enzyme preparations based on the
human gene sequence but differ in the cell type involved in
their production: Imiglucerase is generated from Chinese
Hamster ovary cells, velaglucerase alfa is generated from
human fibroblast-like cell line and taliglucerase alfa is gener-
ated from a carrot cell line. Each formulation is modified to
expose the alpha-mannosyl (carbohydrate) residues for
enhanced uptake by the macrophage:
3.1.1. Imiglucerase and velaglucerase alfa
Imiglucerase and velaglucerase alfa are produced in different
mammalian cell system and require production glycosylation
modifications to expose terminal alpha-mannose residues,
which are needed for mannose receptor-mediated uptake by
target macrophages: such modifications add to production
costs [21]. Side effects are few including pruritis which can be
controlled by antihistaminics. Antibody formation has been
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sus 1%) but in most cases the patient is asymptomatic [22].
3.1.2. Taliglucerase (Elelyso)
It is a plant cell expressed enzyme using carrot root cell cul-
tures using recombinant DNA technology. It is approved by
FDA on May 1st, 2012 for ERT in adults with symptomatic
GD. It does not require additional processing for
post-production glycosidic modifications [21]. It is a safe and
efficacious initial therapy in adults and pediatric patients with
symptomatic GD as well as for those previously treated with
Imiglucerase. It can be used also for treatment of hematologi-
cal manifestations of GD type III [23]. It is administered in a
dose of either 30 units/kg or 60 units/kg in type I GD. It
reduces the spleen and liver volumes by 29–40% and improves
platelet counts and hemoglobin levels. It is also effective in
maintaining spleen and liver volumes, platelet counts, hemo-
globin levels as well as biomarker levels over a 6–9 month eval-
uation period in type I GD switched from imiglucerase [21,23].
The most common side effects reported were transient and
included infusion reactions, allergic reactions and anaphylaxis.
Infusion reactions occur within 24 h of infusion in 44–46% of
treated cases [24]. These include headache, chest pain or dis-
comfort, weakness, fatigue, skin redness, increased blood pres-
sure, back pain, joint pain and flushing. Allergic reactions
includes angioedema, wheezing and hypotension. Anaphylaxis
has been observed in some patients during infusion. In 10% of
cases urinary tract infection, common clod like symptoms,
arthralgia, headache were also observed. Hypersensitivity reac-
tion occurred and included swelling under the skin, flushing,
redness, rash, nausea, vomiting and chest tightness [23,24].
3.1.3. Alglucerase (Ceredase)
This is a placental derived macrophage-targeted GC first intro-
duced in 1991. It leads to reduction in hepatosplenomegaly,
improvement of hypersplenism, decreased biomarkers and
amelioration of bone pain, it has a reliable safety profile.
The original dosage used was 60 units/kg of body weight
(BW) every other week (the high-dose regime), which is still
the most frequently used in clinical trials and accordingly
highly promoted by the manufacturers. [25–28].
3.2. Oral substrate reduction therapy (SRT)
The goal of SRT is tominimize the accumulation of excessmate-
rial (glucosylceramide) within cells by inhibiting the appropriate
synthetic enzyme (glucosylceramide synthase). This will lead to
decreased production of dangerous lipids and the ability of the
residual enzyme to establish a new steady state [29] and so it
(Miglustat) was approved to treat mild to moderate type I
GD. Although it can cross the blood–brain barrier, it proved
to be non effective in neuropathic forms of GD type III [30].
Reported side effects included significant diarrhea, weight
loss, tremors and paresthesia [31]. These sides effects were
overcomed by a recent FDA approved drug, Eliglustat, a novel
agent with better safety profile and higher efficacy. It does not
inhibit intestinal enzymes and so does not cause diarrhea [32].
Also, it has less neurological side effects because it is immedi-
ately transported back out of the CNS by a multidrug trans-
porter [33]. This also suggests that eliglustat would have little
utility for treating neuronopathic forms of GD [32,34].A statistically significant reduction in spleen and liver vol-
umes as well as significant increase in hemoglobin levels and
platelet counts were documented after 9 months of treatment
with Eliglustat. Moreover, no patient discontinued treatment
because of side effects in the recently published report of phase
three clinical trial [35].
The choice of therapy between different drugs of ERT or
SRT should depend on many factors including symptoms,
patient’s age and need, preference and availability of each type
of therapy. Currently, Eliglustat is approved for patients older
than 18 years while ERT can be given to both children and
adults [36].
3.3. Pharmacological chaperon therapy (PCT)
Pharmacological chaperon therapy (PCT) are competitive
reversible active site inhibitors that selectively bind and stabi-
lize the mutant misfolded GC enzyme, thus prevent endoplas-
mic reticulum (ER), associated degradation in proteosome,
restore enzymatic activity and clear stored substrate [37]. It
also facilitates trafficking of the enzyme to the lysosomes,
and have the potential to attenuate the unfolded protein
response and prevent ER stress that can lead to apoptosis
and inflammatory response [38]. This approach is especially
applicable in GD because only a modest increase in residual
GC should be sufficient to ameliorate the phenotype.
Another advantage is that PCT can cross the BBB and can
be orally available. Combination of ERT and PCT should
enhance the effect of ERT, since PCT assists in trafficking
of the endogenous mutant GC out of the ER to lysosomes
where they may have some residual activity. PCT can also
stabilize the recombinant enzyme and increase its half-life
in the circulation [39]. The fact that PCs are less expensive,
can be given orally and usually cross the BBB, opens up
the possibility of treating Type II and Type III GD patients
with neurological involvement that are not responsive to
ERT.
3.3.1. Isofagamine (IFG)
The pharmacological chaperon iminosugar isofagamine (IFG),
have shown these properties in cultured fibroblasts in vivo.
This iminosugar can bind, stabilize and promote lysosomal
trafficking and increase activity of N370S mutant form of
the enzyme GC in cultured fibroblasts in vivo as well as in mice
for GCase mutations: V394L, D409H, or D409V [37,40]. IFG
can also increase the lysosomal activity of L444p mutant form
of GC enzyme in cells and tissues. IFG has also a broad tissue
distribution including access to the CNS and multiple tissues
thus merit therapeutic option for patients with neuropathic
and non-neuropathic GD [41].
3.3.2. Ambroxol
Ambroxol, a mucolytic agent, is also a potential pharmaco-
logic GBA chaperone [42]. It has an advantage of its long his-
tory use in humans and its very low level of toxicity.
3.3.3. Bicyclic L-idonojirimycin
Bicyclic L-idonojirimycin derivative has been suggested as a
potential therapeutic option acting as PCT for patients with
homozygous L444P mutations [43].
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associated with mitochondrial dysfunction. Supplementation
of Coenzyme Q10 (CoQ), together with PCT have resulted in
restoring enzyme folding and trafficking in fibroblasts. It also
improved mitochondrial function and the associated patho-
physiological alterations [44].
3.4. Bone marrow (BM) transplantation
For GD and other lysosomal disorders, wild-type donor BM
transplantation has been used because monocytes from the
peripheral blood can migrate across the BBB and become
CNS microglial cells that could affect metabolic cross correc-
tion. BM or stem cell transplantation has not been effective
for the CNS disease because of the lack of secretable enzyme
[45]. Induced pluripotent stem cells are an attractive alternative
for generating either hematologic progenitor cells or neural
progenitor cells for direct cellular and/or enhanced gene ther-
apy [46].
3.5. Symptom management and care
This includes various pain reduction therapies, blood transfu-
sions, orthopedic surgery for bone and joints and rarely
splenectomy. We should not forget routine follow-up for all
treated patients, children, and untreated adult patients with
unstable parameters; and annual evaluations for adults with
stable disease [47].
3.5.1. Partial or total splenectomy
Persistent thrombocytopenia in GD patients treated with ERT
for over 4 years relates to refractory splenomegaly. Therefore,
life-threatening thrombocytopenia may be one of the few cir-
cumstances where splenectomy may still be justified in GD [48].
3.5.2. Transfusion of blood products
Transfusion of blood products for severe anemia and bleeding.
Anemia and clotting problems unresponsive to ERT should
prompt investigations for an intercurrent disease process.
Evaluation by a hematologist is recommended prior to any
major surgical or dental procedures or parturition [49].
3.5.3. Bisphosphonate: it can be effective and safe
The use of biphosphonates can be an effective and safe mean
to increase bone density and prevent complications [50]. Sup-
portive management for bone pains or bone crises is frequently
required, and orthopedic surgery may be necessary in cases of
pathologic fractures or osteonecrosis [51].
3.6. Psychological care
Psychological care to reduce mental and emotional impact of
disease on patients and their families.
3.7. Professional genetic counseling
Professional genetic counseling to help parents to prevent birth
of other affected children by explaining that the disease is an
autosomal recessive disease with 25% recurrence risk and
75% chance to have normal children in each pregnancy.Prenatal diagnosis by enzyme assay or molecular studies are
both available.
3.8. Gene therapy
Limited trials on GD mouse models showed an evidence for
the possibility of developing safe and efficient conditioning
protocols for diseases that require only a low level of normal
or gene-corrected cells for a permanent and beneficial thera-
peutic outcome. Although some enzyme has been produced
by transduced cells, enzyme production does not appear to
be sustained and therefore does not result in a permanent cure.
It is anticipated that transduced cells would not have a prolif-
erative advantage over uncorrected cells. Furthermore, it is
unlikely that significant metabolic cross-correction would
occur as only small amounts of enzyme are secreted into the
circulation [52].
In conclusion, several options for the treatment of GD are
currently available, the choice of which will depend on many
factors including age of patient, availability of drug, cost and
side effects. Future therapies will also be offered in the near
future with potential efficiency in crossing the BBB and there-
fore more effective in the neuropathic form.
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